Amar Kishan
@AmarUKishan
Followers
4K
Following
7K
Statuses
3K
Radiation Oncologist, Professor, and Executive Vice Chair of Radiation Oncology at UCLA. All views are my own.
Joined November 2017
It’s a pleasure to announce the appointment of Dr. @AmarUKishan to Executive Vice Chair for the Department of Radiation Oncology at the David Geffen School of Medicine at UCLA and the UCLA Jonsson Comprehensive Cancer Center.
14
1
94
@VedangMurthy @alison_tree @DrAndrewLoblaw @CZamboglou @piet_ost @TylerSbrt @SbrtSean @indranilsays @EmmaHall71 Very practical and useful work!
0
0
4
RT @_ShankarSiva: 📢🚨 Hot off the press @TheLancetOncol for #kidneycancer! SABR vs thermal ablation; - Despite ⏫age…
0
87
0
RT @VedangMurthy: 👨⚕️ Resident (@akshay_dinesan ): "Sir, how should we contour the bowel for WP-SBRT in #prostatecancer? Bowel bag or loop…
0
43
0
RT @UrologyTimes: Amar Kishan, MD, (@AmarUKishan) touches on the implications of findings from the MIRAGE trial, which showed that aggressi…
0
3
0
RT @montypal: I would love to get some more poster submissions from our talented Southern California trainees! Please consider submitting y…
0
17
0
RT @montypal: A meeting for my #SoCal colleagues. No lengthy travel required. Join us in #NewportBeach to discuss the current status of cli…
0
13
0
@piet_ost @PCaParker @UCLAHealth @TheLancetOncol Certainly. The broader point is the principle, which is illustrated in this analysis (link between acute and late). It would seem easier to limit acute (optimize baseline symptoms, improve dose delivery, margin reduction, etc.) than to try to mitigate late toxicity later.
0
1
4
@piet_ost @PCaParker @UCLAHealth @TheLancetOncol For our PRO analysis (which included 3 of the trials), we looked at 2xMCID (which was based on baseline QOL scores). However, no, baseline toxicity was not uniformly available across all 6 trials.
1
0
2
RT @UrologyTimes: WATCH: Amar U. Kishan, MD, (@AmarUKishan) discusses the rationale for the initiation and design of the MIRAGE trial. @Ucl…
0
3
0
RT @NiuSanford: Last week @drdavidpalma came to UTSW & gave an outstanding talk on oligomets. I thought this slide was pretty perfect 😳. h…
0
16
0
RT @NiuSanford: I think the NIH/NCI should create its own FREE open access journal and 1) Publish all NIH funded research 2) Pay reviewers…
0
199
0
RT @CZamboglou: Excited to share two major milestones of our global Co-IMPACT project: ➡️Homepage is live: ➡️New pa…
0
16
0
RT @montypal: Several years ago, @siadaneshmand & I teamed w @TDorffOnc, @KidneyCancerDoc, @AdityaBagrodia, @AmarUKishan, @DrRanaMcKay & se…
0
22
0
RT @CalaisJeremie: Low- and High-Volume Disease in mHSPC: from CHAARTED to #PSMA PET #stagemigration
@UnterrainerL…
0
26
0
RT @VedangMurthy: With the new year, comes new insight. Is 25Gy/5# enough for prophylactic nodal RT in high-risk #ProstateCancer? Borrowed…
0
56
0
RT @JennKa12: 💥 Urethra-sparing prostate cancer radiotherapy: Current practices and future insights from an international survey https://t…
0
17
0